Knockdown of scavenger receptor Class B Type i reduces prostate specific antigen secretion and viability of prostate cancer cells

Prostate

Volumn 72, Issue 9, 2012, Pages 955-965

  Twiddy, Alexis L ^a   Cox, Michael E ^b   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

cholesterol; HMG CoA reductase; prostate; PSA; SR BI

Indexed keywords

ACETIC ACID; CARBON 14; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CELL VIABILITY; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR DOWN REGULATION;

CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SCAVENGER RECEPTORS, CLASS B;

EID: 84861098194     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21499     Document Type: Article

References (66)

1. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
2. Schroder FH,. Progress in understanding androgen-independent prostate cancer (AIPC): A review of potential endocrine-mediated mechanisms. Eur Urol 2008; 53 (6): 1129-1137.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39.
4. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS,. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008; 68 (11): 4447-4454.
5. Mostaghel EA, Nelson PS,. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 2008; 22 (2): 243-258.
6. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME, Nelson CC,. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68 (15): 6407-6415.
7. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM,. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61 (7): 2892-2898.
8. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448.
9. Twiddy AL, Leon CG, Wasan KM,. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm Res 2011; 28 (3): 423-437.
10. Locke JA, Fazli L, Adomat H, Smyl J, Weins K, Lubik AA, Hales DB, Nelson CC, Gleave ME, Tomlinson Guns ES,. A novel communication role for CYP17A1 in the progression of castration-resistant prostate cancer. Prostate 2009; 69 (9): 928-937.
11. Ikonen E,. Cellular cholesterol trafficking compartmentalization. Nat Rev Mol Cell Biol 2008; 9 (2): 125-138.
12. Jonas A,. Chapter 18: Lipoprotein structure. In:, Vance DE, Vance JE, editors. Biochemistry of lipids, lipoproteins and membranes, 4th edition. Elsevier; 2002. p 484-490.
13. Chang TY, Chang CC, Ohgami N, Yamauchi Y,. Cholesterol sensing, trafficking, and esterification. Annu Rev Cell Dev Biol 2006; 22: 129-157.
14. Connelly MA,. SR-BI-mediated HDL cholesteryl ester delivery in the adrenal gland. Mol Cell Endocrinol 2009; 300 (1-2): 83-88.
15. Connelly MA, Williams DL,. SR-BI and HDL cholesteryl ester metabolism. Endocr Res 2004; 30 (4): 697-703.
16. Calvo D, Vega MA,. Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family. J Biol Chem 1993; 268 (25): 18929-18935.
17. Rhainds D, Brissette L,. The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders. Int J Biochem Cell Biol 2004; 36 (1): 39-77.
18. Saddar S, Mineo C, Shaul PW,. Signaling by the high-affinity HDL receptor scavenger receptor B type I. Arterioscler Thromb Vasc Biol 2010; 30 (2): 144-150.
19. Krieger M,. Charting the fate of the "good cholesterol;" Identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem 1999; 68: 523-558.
20. Reaven E, Lua Y, Nomoto A, Temel R, Williams DL, van der Westhuyzen DR, Azhar S,. The selective pathway and a high-density lipoprotein receptor (SR-BI) in ovarian granulosa cells of the mouse. Biochim Biophys Acta 1999; 1436 (3): 565-576.
21. Zimetti F, Weibel GK, Duong M, Rothblat GH,. Measurement of cholesterol bidirectional flux between cells and lipoproteins. J Lipid Res 2006; 47 (3): 605-613.
22. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG,. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 2008; 19 (2): 183-188.
23. Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM,. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010; 70 (4): 390-400.
24. Mooberry LK, Nair M, Paranjape S, McConathy WJ, Lacko AG,. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target 2009; 18 (1): 53-58.
25. Ni J, Pang ST, Yeh S,. Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Prostate 2007; 67 (5): 463-471.
26. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, Nelson CC,. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004; 64 (6): 2212-2221.
27. Krycer JR, Kristiana I, Brown AJ,. Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3. PLoS One 2009; 4 (12): e8496.
28. Chen Y, Hughes-Fulford M,. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 2001; 91 (1): 41-45.
29. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW,. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int J Cancer 1994; 57 (3): 406-412.
30. Zhao M, Yang H, Jiang X, Zhou W, Zhu B, Zeng Y, Yao K, Ren C,. Lipofectamine RNAiMAX: An efficient siRNA transfection reagent in human embryonic stem cells. Mol Biotechnol 2008; 40 (1): 19-26.
31. Locke JA, Wasan KM, Nelson CC, Guns ES, Leon CG,. Androgen-mediated cholesterol metabolism in LNCaP and PC-3 cell lines is regulated through two different isoforms of acyl-coenzyme A:Cholesterol Acyltransferase (ACAT). Prostate 2008; 68 (1): 20-33.
32. Sachs-Barrable K, Thamboo A, Lee SD, Wasan KM,. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2cells. J Pharm Pharm Sci 2007; 10 (3): 319-331.
33. Connelly-Smith L, Pattinson J, Grundy M, Shang S, Seedhouse C, Russell N, Pallis M,. P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors. Exp Hematol 2007; 35 (12): 1793-1800.
34. Bligh EG, Dyer WJ,. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37 (8): 911-917.
35. Plump AS, Erickson SK, Weng W, Partin JS, Breslow JL, Williams DL,. Apolipoprotein A-I is required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest 1996; 97 (11): 2660-2671.
36. Azhar S, Reaven E,. Scavenger receptor class BI and selective cholesteryl ester uptake: Partners in the regulation of steroidogenesis. Mol Cell Endocrinol 2002; 195 (1-2): 1-26.
37. Kraemer FB, Shen WJ, Patel S, Osuga J, Ishibashi S, Azhar S,. The LDL receptor is not necessary for acute adrenal steroidogenesis in mouse adrenocortical cells. Am J Physiol Endocrinol Metab 2007; 292 (2): E408-E412.
38. Hersberger M, von Eckardstein A,. Low high-density lipoprotein cholesterol: Physiological background, clinical importance and drug treatment. Drugs 2003; 63 (18): 1907-1945.
39. Rhainds D, Bourgeois P, Bourret G, Huard K, Falstrault L, Brissette L,. Localization and regulation of SR-BI in membrane rafts of HepG2cells. J Cell Sci 2004; 117 (Pt 15): 3095-3105.
40. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, von Dehn G, Jansen H, Assmann G, von Eckardstein A,. Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun 2002; 296 (5): 1051-1057.
41. Pal A, Ahmad A, Khan S, Sakabe I, Zhang C, Kasid UN, Ahmad I,. Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 2005; 26 (4): 1087-1091.
42. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, Janke O, Endruschat J, Durieux B, Roder N, Loffler K, Lange C, Fechtner M, Mopert K, Fisch G, Dames S, Arnold W, Jochims K, Giese K, Wiedenmann B, Scholz A, Kaufmann J,. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008; 68 (23): 9788-9798.
43. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, Hsieh CL,. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther 2005; 12 (4): 634-643.
44. Weyermann J, Lochmann D, Zimmer A,. A practical note on the use of cytotoxicity assays. Int J Pharm 2005; 288 (2): 369-376.
45. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, Visakorpi T,. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69 (20): 8141-8149.
46. Brown MS, Goldstein JL,. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232 (4746): 34-47.
47. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL,. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164 (1): 217-227.
48. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W, Verhoeven G,. Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 2004; 92 (4): 273-279.
49. Lee MY, Moon JS, Park SW, Koh YK, Ahn YH, Kim KS,. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells. Biochem J 2009; 417 (1): 313-322.
50. Brown MS, Goldstein JL, Dietschy JM,. Active and inactive forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase in the liver of the rat. Comparison with the rate of cholesterol synthesis in different physiological states. J Biol Chem 1979; 254 (12): 5144-5149.
51. Hardie DG,. Minireview: The AMP-activated protein kinase cascade: The key sensor of cellular energy status. Endocrinology 2003; 144 (12): 5179-5183.
52. Kuriyama M,. Prostate-specific antigen in prostate cancer. Int J Biol Markers 1986; 1 (2): 67-76.
53. Rennie PS, Bruchovsky N, Goldenberg SL,. Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 1988; 11 (Suppl 2): S13-S17.
54. Srinivasan G, Campbell E, Bashirelahi N,. Androgen, estrogen, and progesterone receptors in normal and aging prostates. Microsc Res Tech 1995; 30 (4): 293-304.
55. Bilhartz DL, Tindall DJ, Oesterling JE,. Prostate-specific antigen and prostatic acid phosphatase: Biomolecular and physiologic characteristics. Urology 1991; 38 (2): 95-102.
56. Bonaccorsi L, Nosi D, Quercioli F, Formigli L, Zecchi S, Maggi M, Forti G, Baldi E,. Prostate cancer: A model of integration of genomic and non-genomic effects of the androgen receptor in cell lines model. Steroids 2008; 73 (9-10): 1030-1037.
57. Cinar B, Mukhopadhyay NK, Meng G, Freeman MR,. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem 2007; 282 (40): 29584-29593.
58. Hakariya T, Shida Y, Sakai H, Kanetake H, Igawa T,. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells. Biochem Biophys Res Commun 2006; 342 (1): 92-100.
59. Kawamura S, Sato I, Wada T, Yamaguchi K, Li Y, Li D, Zhao X, Ueno S, Aoki H, Tochigi T, Kuwahara M, Kitamura T, Takahashi K, Moriya S, Miyagi T,. Plasma membrane-associated sialidase (NEU3) regulates progression of prostate cancer to androgen-independent growth through modulation of androgen receptor signaling. Cell Death Differ 2011; [Epub Ahead of Print].
60. Yang L, Egger M, Plattner R, Klocker H, Eder IE,. Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells. Urology 2011; 77 (6): 1508, e1501-1507.
61. Murao K, Imachi H, Cao W, Yu X, Li J, Yoshida K, Ahmed RA, Matsumoto K, Nishiuchi T, Wong NC, Ishida T,. High-density lipoprotein is a potential growth factor for adrenocortical cells. Biochem Biophys Res Commun 2006; 344 (1): 226-232.
62. Sekine Y, Suzuki K, Remaley AT,. HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145cells via ERK1/2 and S1P receptors, and promote cell migration and invasion. Prostate 2010; [Epub Ahead of Print].
63. Al-Jarallah A, Trigatti BL,. A role for the scavenger receptor, class B type I in high density lipoprotein dependent activation of cellular signaling pathways. Biochim Biophys Acta 2010; 1801 (12): 1239-1248.
64. Mineo C, Shaul PW,. HDL stimulation of endothelial nitric oxide synthase: A novel mechanism of HDL action. Trends Cardiovasc Med 2003; 13 (6): 226-231.
65. Mineo C, Yuhanna IS, Quon MJ, Shaul PW,. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 2003; 278 (11): 9142-9149.
66. Mulay V, Wood P, Rentero C, Enrich C, Grewal T,. Signal transduction pathways provide opportunities to enhance HDL and apoAI-dependent reverse cholesterol transport. Curr Pharm Biotechnol 2011; [Epub Ahead of Print].